Redhill Biopharma (RDHL) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Traws Pharma is the larger company by market cap ($2.7 million vs $2.5 million), about 1.1 times the size. Traws Pharma converts more of its revenue into profit, with a net margin of 328.7% versus -102.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RDHL | TRAW |
|---|---|---|
| Share price | $0.281 | $0.175 |
| Market cap | $2.50M | $2.69M |
| 1-day change | -13.08% | -23.91% |
| Forward P/E | 9.37 | — |
| EPS (TTM) | $0.00 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.04M | $2.79M |
| Revenue growth (YoY) | +23.17% | +1134.51% |
| Net income (latest FY) | $-8.27M | $9.17M |
| Gross margin | 60.31% | — |
| Operating margin | -181.69% | -640.68% |
| Net margin | -102.80% | 328.67% |
| 52-week high | $1.60 | $3.23 |
| 52-week low | $0.281 | $0.1698 |
| Distance from 52-week high | -82.44% | -94.58% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +471.43% |
| Average volume | 2.08M | 610.04K |
| Shares outstanding | 8.89M | 15.37M |
| Employees | 13 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Traws Pharma is more profitable, keeping 328.7 cents of every revenue dollar as net income versus -102.8 cents for Redhill Biopharma.
- Traws Pharma grew revenue faster in its latest fiscal year (+1134.51% vs +23.17%).
About Redhill Biopharma
RDHL stock →RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
RDHL vs TRAW FAQ
Which is bigger, Redhill Biopharma or Traws Pharma?
Traws Pharma (TRAW) is larger, with a market capitalization of $2.69M compared with $2.50M for Redhill Biopharma (RDHL).
Are Redhill Biopharma and Traws Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.